Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹8,739Cr
Rev Gr TTM
Revenue Growth TTM
4.35%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

CLEAN
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 6.0 | -19.6 | -26.8 | -18.0 | 4.9 | 19.1 | 31.5 | 23.7 | 15.9 | 8.4 | 2.8 | -8.8 |
| 112 | 112 | 106 | 108 | 133 | 129 | 148 | 142 | 159 | 143 | 158 | 147 |
Operating Profit Operating ProfitCr |
| 48.5 | 40.5 | 41.3 | 44.5 | 41.5 | 42.3 | 37.7 | 40.9 | 39.7 | 41.1 | 35.6 | 32.9 |
Other Income Other IncomeCr | 13 | 13 | 6 | 8 | 14 | 10 | 11 | 5 | 12 | 13 | 7 | 10 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 10 | 11 | 11 | 11 | 13 | 16 | 18 | 18 | 17 | 19 | 19 | 19 |
| 108 | 79 | 69 | 83 | 95 | 89 | 83 | 85 | 100 | 95 | 75 | 63 |
| 27 | 20 | 17 | 20 | 25 | 23 | 24 | 20 | 25 | 24 | 19 | 17 |
|
Growth YoY PAT Growth YoY% | 29.1 | -6.3 | -23.2 | -25.3 | -12.7 | 11.9 | 12.6 | 4.8 | 5.4 | 6.3 | -5.7 | -30.1 |
| 37.1 | 31.3 | 28.8 | 32.2 | 30.9 | 29.4 | 24.7 | 27.3 | 28.1 | 28.9 | 22.6 | 20.9 |
| 7.6 | 5.5 | 4.9 | 5.9 | 6.6 | 6.2 | 5.5 | 6.2 | 7.0 | 6.6 | 5.2 | 4.3 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 63.1 | 6.6 | 22.2 | 33.7 | 36.6 | -15.4 | 22.1 | 0.5 |
| 168 | 257 | 234 | 253 | 385 | 534 | 459 | 579 | 607 |
Operating Profit Operating ProfitCr |
| 30.4 | 34.7 | 44.2 | 50.5 | 43.8 | 43.0 | 42.0 | 40.1 | 37.5 |
Other Income Other IncomeCr | 5 | 11 | 11 | 26 | 30 | 30 | 41 | 39 | 42 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Depreciation DepreciationCr | 8 | 11 | 14 | 17 | 25 | 36 | 46 | 69 | 74 |
| 70 | 137 | 182 | 267 | 305 | 396 | 327 | 357 | 332 |
| 21 | 39 | 43 | 69 | 76 | 100 | 82 | 92 | 86 |
|
| | 99.7 | 43.0 | 42.1 | 15.2 | 29.2 | -17.3 | 8.3 | -7.2 |
| 20.3 | 24.8 | 33.3 | 38.7 | 33.4 | 31.5 | 30.8 | 27.4 | 25.3 |
| 4.6 | 9.2 | 13.2 | 18.7 | 21.5 | 27.8 | 23.0 | 24.9 | 23.1 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 1 | 1 | 1 | 11 | 11 | 11 | 11 | 11 | 11 |
| 186 | 271 | 341 | 529 | 758 | 999 | 1,193 | 1,406 | 1,489 |
Current Liabilities Current LiabilitiesCr | 38 | 41 | 77 | 102 | 135 | 116 | 161 | 156 | 150 |
Non Current Liabilities Non Current LiabilitiesCr | 10 | 14 | 11 | 18 | 21 | 26 | 35 | 36 | 35 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 125 | 193 | 257 | 395 | 570 | 630 | 660 | 799 | 804 |
Non Current Assets Non Current AssetsCr | 111 | 135 | 173 | 265 | 354 | 521 | 739 | 809 | 880 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 45 | 85 | 160 | 193 | 127 | 279 | 236 | 214 |
Investing Cash Flow Investing Cash FlowCr | -18 | -95 | -106 | -187 | -79 | -270 | -185 | -152 |
Financing Cash Flow Financing Cash FlowCr | -5 | -11 | -55 | -6 | 0 | -55 | -53 | -53 |
|
Free Cash Flow Free Cash FlowCr | 13 | 46 | 110 | 109 | -12 | 96 | 10 | 72 |
| 92.0 | 86.8 | 114.7 | 97.2 | 55.7 | 94.6 | 96.9 | 80.9 |
CFO To EBITDA CFO To EBITDA% | 61.3 | 62.2 | 86.4 | 74.5 | 42.4 | 69.5 | 71.2 | 55.2 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 21,170 | 13,432 | 14,111 | 12,404 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 92.7 | 45.5 | 57.8 | 46.9 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 30.9 | 14.3 | 17.8 | 12.8 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 27.6 | 13.3 | 11.7 | 8.8 |
| -0.4 | -0.1 | 0.0 | -0.1 | 70.3 | 33.4 | 42.5 | 31.9 |
Profitability Ratios Profitability Ratios |
| 53.0 | 56.5 | 69.2 | 75.9 | 67.2 | 65.2 | 65.0 | 63.7 |
| 30.4 | 34.7 | 44.2 | 50.5 | 43.8 | 43.0 | 42.0 | 40.1 |
| 20.3 | 24.8 | 33.3 | 38.7 | 33.4 | 31.5 | 30.8 | 27.4 |
| 37.4 | 49.7 | 52.9 | 49.5 | 39.7 | 39.1 | 27.2 | 25.2 |
| 26.0 | 35.9 | 40.8 | 36.8 | 29.7 | 29.2 | 20.3 | 18.7 |
| 20.7 | 29.8 | 32.5 | 30.1 | 24.7 | 25.6 | 17.4 | 16.4 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Company Overview**
**Clean Science & Technology Limited (CSTL)** is a leading Indian specialty and fine chemical manufacturer established in 2003, headquartered in Pune, Maharashtra. The company operates as a B2B global supplier with a strong focus on **green chemistry, catalytic innovation, and atom-efficient processes**. CSTL is recognized as one of the world’s largest producers of several key specialty chemicals, with an export footprint spanning **over 35 countries**, contributing more than **60–72% of total revenues from international markets**.
CSTL serves three primary business segments:
1. **Performance Chemicals (67–70% of revenue)**
2. **Pharma & Agro Intermediates (19%)**
3. **FMCG Chemicals (12%)**
The company is led by Promoter-Executive Directors with deep expertise in catalytic and clean technologies, and it operates four manufacturing units within the MIDC Kurkumbh, Pune cluster, each equipped with **zero liquid discharge (ZLD)** systems, in-house R&D, and independent utilities for operational resilience.
---
### **Strategic Transformation: From Supplier to Co-Development Partner**
CSTL is undergoing a strategic evolution from a **product-centric model to a customer co-creation and co-development partner**. Key initiatives include:
- **Deployment of Technical Account Managers (TAMs)** in key regions to align commercial teams with R&D and accelerate customer onboarding.
- **Establishment of an Application Laboratory** (commissioned in 2024–25) enabling polymer, masterbatch, and coatings customers to test HALS products under real-world conditions — reducing validation timelines and enhancing customer confidence.
- **Hybrid Go-to-Market Model**: Combines direct global engagement with select distributors to balance market reach and responsiveness.
- Emphasis on **technical support**, including formulation assistance, regulatory guidance, and application testing, to deepen strategic customer relationships beyond transactional sales.
---
### **Core Strengths & Differentiation**
#### 1. **Green Chemistry & Sustainable Manufacturing**
CSTL is a pioneer in **eco-friendly, catalytic-based chemical synthesis**:
- Operates all plants as **Zero Liquid Discharge (ZLD)** facilities, using advanced aerobic and anaerobic effluent systems.
- Developed the **only commercial vapor-phase process globally** for manufacturing **Anisole from Phenol**, which produces only water as a byproduct — a breakthrough in waste prevention.
- Proprietary **in-house catalysts** reduce dependence on toxic reagents, lower effluent generation, and improve atom economy and yield.
- Solvent recovery and closed-loop processes minimize environmental impact and operating costs.
#### 2. **R&D-Led Innovation & Pipeline**
- Employs **~90 scientists**, including **9 PhDs**, across **four dedicated 24x7 R&D labs** and a state-of-the-art **pilot facility**.
- R&D is **central to strategy**, not a support function, focused on:
- Green chemistry
- Atom economy
- Catalytic efficiency
- Rapid scale-up
- Maintains a **continuous pipeline of 10+ new molecules** in development across performance chemicals, pharma, and FMCG.
- In FY2024–25, achieved the **highest number of new product launches in its history**, including the full HALS series and DHDT.
#### 3. **Backward Integration & In-House Process Expertise**
- Fully backward integrated into key raw materials like **Anisole (world’s largest producer)**, **phenol, methanol**, and other intermediates.
- Operates proprietary catalytic systems using technologies such as:
- Vapour-phase reactions
- Continuous flow reactors
- Hydrogenation
- Triphasic ring formation
- Chlorination
- Esterification and hydroamination
---
### **Key Product Milestones & Portfolio Expansion (2024–2026)**
| Product / Segment | Key Highlights |
|------------------|----------------|
| **HALS (Hindered Amine Light Stabilizers)** | - Became the **first Indian company** and **fifth globally** to achieve **full backward integration** and commercial scale in the complete HALS series.<br>- Commercialized 5 grades: **770, 622, 944, 119, 2020**.<br>- Scaled up production using advanced catalytic methods, reducing input intensity and complexity.<br>- REACH-certified, exported to US, Europe, Turkey, Southeast Asia, and China.<br>- India currently imports ~3,000 tons/year of HALS; CSTL targets rapid domestic market capture with competitive pricing and just-in-time delivery. |
| **DHDT (2,5-Dihydroxy-1,4-Dithiane)** | - Critical **pharmaceutical intermediate** for antiretroviral APIs.<br>- Developed via proprietary **chlorination chemistry** as an export-substituted product.<br>- Production commenced December 2024 at **Clean Fino-Chem Limited (CFCL)**.<br>- Enhances CSTL’s presence in regulated global pharma markets.<br>- Supports **India’s Aatmanirbhar Bharat initiative**. |
| **Performance Chemicals** | - Flagship products: **MEHQ (world’s largest producer)**, **BHA**, **TBHQ**, **Ascorbyl Palmitate (AP)**, **4-MAP**, **Guaiacol**, **Veratrole**, **Anisole**.<br>- Expanding into **UV stabilizers, antioxidants, and polymer additives**.<br>- 4-MAP and Anisole: both ranked **#1 global suppliers**; used in sunscreens, perfumes, and pharma. |
| **Pharma & Agro Intermediates** | - Key products: **DCC (sulphur-free, globally unique)**, **Guaiacol**, **Veratrole**, **DHDT**, **Barbituric Acid (repurposed PBQ plant)**.<br>- CSTL is **No. 1 in India** and **No. 2 globally** in DCC and Guaiacol production. |
---
### **Clean Fino-Chem Limited (CFCL) – Growth Engine**
- **Wholly-owned greenfield subsidiary** established on a **34-acre site** in Kurkumbh.
- **India’s largest dedicated HALS production facility**, representing CSTL’s biggest CAPEX project to date (investment of **₹3,851 million** funded via internal accruals).
- **Concessional tax rate of 17.16%** (vs. standard 25.17%), enhancing ROI and future project attractiveness.
- Hosts **India’s first end-to-end HALS manufacturing infrastructure** with full backward integration.
- **Operational since March 2021**; commercialized **DHDT and multiple HALS grades**.
- **Expected to operate at full design capacity in FY2025–26**, with phased launch of new products.
- **On-site Application Lab** supports customer validation and co-innovation.
- **Planned INR 300 crore expansion (FY2025–26)** for high-growth performance chemicals, leveraging CFCL’s modular infrastructure.
---
### **Market Position & Financial Highlights (FY2024–2025)**
- **Record Consolidated Revenue**: **INR 950 Crores** in FY2025.
- **Over 25% of revenue from new products** (HALS, DHDT, BHT, Performance Chemicals 1 & 2).
- **EBITDA Margin**: ~41%, reflecting strong cost control and operational efficiency.
- **Exports**: >60% of revenue, with major markets being **China (34%)**, **Americas & Europe (16% each)**, **India (28%)**, and rest of world.
- **HALS sales volume grew 3.3x YoY** to **over 1,900 tons** in FY2025.
- **Customer Base**: Over **500 global and domestic clients**.
---
### **Competitive Landscape & Strategy**
- **Primary HALS Competitor**: **Unitechem (Suqian, China)**. Rianlon less of a threat.
- **Differentiation**:
- Proprietary green processes
- Cost-efficient domestic manufacturing
- Full backward integration
- Customer-centric innovation
- **Local Advantage vs. Imports**: Offers **2.5–3% price discount** vs. imported HALS + **just-in-time delivery** and no container shipment constraints.
- **No new Chinese entrants** currently due to weak demand in their export markets.
---
### **Corporate Responsibility & Sustainability**
- **Eco-Initiatives**: Zero liquid discharge, solvent recovery, waste minimization via atom economy.
- **Environmental Recognition**: Silver GreenCo certified — **only Indian specialty chemical company** with this distinction.
- Plans to **plant 11,000 trees** in coming years.
- Compliance with ESG standards in global procurement processes.